Bathi saben saham sajrone rolas wulan pungkasan: Puma Biotechnology Inc (PBYI)

Puma Biotechnology relies on outsourcing for production and testing to maintain workforce flexibility. The 12-month rolling revenue per employee metric on the GURU.Markets chart confirms this trajectory, where 0.46 shows the current value of the metric. However, dependence on a single drug creates margin risks, and a minimal environmental footprint is achieved solely through digital documentation.

This indicator measures annual net income allocated per share, allowing for an objective assessment of the business's real profitability regardless of the total volume of issuance. By analyzing the rolling earnings per share metric, an investor can track the commercialization efficiency of Nerlynx and the ability of Puma Biotechnology (PBYI) management to transform the oncology pipeline into a sustainable financial result for the portfolio.